



1FW


DOCKET NO.: B0801.70255US01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Pier et al.
Serial No.: 10/713,790
Confirmation No.: 5867
Filed: November 12, 2003
For: POLYSACCHARIDE VACCINE FOR STAPHYLOCOCCAL INFECTIONS
Examiner: Sarvamangala J N Devi
Art Unit: 1645

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 9th day of March, 2006.


Emily E. Zukauskas

MAIL STOP AMENDMENT

Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:

- Information Disclosure Statement
- PTO Form 1449 with cited references
- Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 646-8000, Boston, Massachusetts.

A check is not enclosed. If a fee is required, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

By:



Maria A. Trevisan, Reg. No.: 48,207
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: B0801.70255US01
Date: March 9, 2006
xNDDx




DOCKET NO.: B0801.70255US01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Pier et al.
Serial No.: 10/713,790
Confirmation No.: 5867
Filed: November 12, 2003
For: POLYSACCHARIDE VACCINE FOR
STAPHYLOCOCCAL INFECTIONS
Examiner: Sarvamangala J N Devi
Art Unit: 1645

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 9th day of March, 2006.


Emily E. Zukauskas

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**STATEMENT FILED PURSUANT TO THE DUTY OF
DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98**

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing of a first Office action on the merits in the above-identified case.

No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;
3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Serial No.: 10/713,790
Conf. No.: 5867

- 3 -

Art Unit: 1645

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,


By:



Maria A. Trevisan, Reg. No. 48,207
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: B0801.70255US01
Date: March 9, 2006
xNDDx

| | | | | |
|---|--------------------------------|--|-----------------------------------|--|
| FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | APPLICATION NO.: 10/713,790 | | ATTY. DOCKET NO.: B0801.70255US01 | |
| | FILING DATE: November 12, 2003 | | CONFIRMATION NO.: 5867 | |
| | APPLICANT: Pier et al. | | | |
| | GROUP ART UNIT: 1645 | | EXAMINER: Sarvamangala J N Devi | |
| Sheet 1 of 2 | | | | |



U.S. PATENT DOCUMENTS

| Examiner's Initials # | Cite No. | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication or Issue of Cited Document MM-DD-YYYY |
|--------------------------|-------------|----------------------|--------------|--|---|
| | | Number | Kind Code | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner's Initials # | Cite No. | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Translation (Y/N) |
|--------------------------|-------------|-------------------------|-----------|--------------|--|---|----------------------|
| | | Office/ Country | Number | Kind Code | | | |
| | B22 | WO | 03/053462 | A2 | Merck & Co., Inc. | 07-03-2003 | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

OTHER ART — NON PATENT LITERATURE DOCUMENTS

| Examiner's Initials # | Cite No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | Translation (Y/N) |
|--------------------------|------------|---|----------------------|
| | C98 | ALLIGNET et al., Tracking adhesion factors in Staphylococcus caprae strains responsible for human bone infections following implantation of orthopaedic material. Microbiology. 1999 Aug;145 (Pt 8):2033-42. | |
| | C99 | ARCIOLA et al., In catheter infections by Staphylococcus epidermidis the intercellular adhesion (ica) locus is a molecular marker of the virulent slime-producing strains. J Biomed Mater Res. 2002 Mar 5;59(3):557-62. Abstract Only. | |
| | C100 | BHASIN et al., Identification of a gene essential for O-acetylation of the Staphylococcus aureus type 5 capsular polysaccharide. Mol Microbiol. 1998 Jan;27(1):9-21. Abstract Only. | |
| | C101 | CRAMTON et al., The intercellular adhesion (ica) locus is present in Staphylococcus aureus and is required for biofilm formation. Infect Immun. 1999 Oct;67(10):5427-33. | |
| | C102 | CRAMTON et al., Anaerobic conditions induce expression of polysaccharide intercellular adhesin in Staphylococcus aureus and Staphylococcus epidermidis. Infect Immun. 2001 Jun;69(6):4079-85. | |
| | C103 | DOBINSKY et al., Influence of Tn917 insertion on transcription of the icaADBC operon in six biofilm-negative transposon mutants of Staphylococcus epidermidis. Plasmid. 2002 Jan;47(1):10-7. Abstract Only. | |
| | C104 | FATTOM et al., Antigenic determinants of Staphylococcus aureus type 5 and type 8 capsular polysaccharide vaccines. Infect Immun. 1998 Oct;66(10):4588-92. | |

| | |
|-----------|------------------|
| EXAMINER: | DATE CONSIDERED: |
|-----------|------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

| | | | | | |
|---|---|----|---|--------------------------------|-----------------------------------|
| FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICATION NO.: 10/713,790 | ATTY. DOCKET NO.: B0801.70255US01 |
| | | | | FILING DATE: November 12, 2003 | CONFIRMATION NO.: 5867 |
| | | | | APPLICANT: Pier et al. | |
| | | | | GROUP ART UNIT: 1645 | EXAMINER: Sarvamangala J N Devi |
| Sheet | 2 | of | 2 | | |

| | | | |
|--|------|---|--|
| | C105 | FEY et al., Characterization of the relationship between polysaccharide intercellular adhesin and hemagglutination in Staphylococcus epidermidis. J Infect Dis. 1999 Jun;179(6):1561-4. Abstract Only. | |
| | C106 | FOWLER et al., The intercellular adhesin locus ica is present in clinical isolates of Staphylococcus aureus from bacteremic patients with infected and uninfected prosthetic joints. Med Microbiol Immunol (Berl). 2001 Apr;189(3):127-31. Abstract Only. | |
| | C107 | FREBOURG et al., PCR-Based assay for discrimination between invasive and contaminating Staphylococcus epidermidis strains. J Clin Microbiol. 2000 Feb;38(2):877-80. | |
| | C108 | GELOSIA et al., Phenotypic and genotypic markers of Staphylococcus epidermidis virulence. Clin Microbiol Infect. 2001 Apr;7(4):193-9. Abstract Only. | |
| | C109 | HEILMANN et al., Further characterization of Staphylococcus epidermidis transposon mutants deficient in primary attachment or intercellular adhesion. Zentralbl Bakteri. 1998 Jan;287(1-2):69-83. Abstract Only. | |
| | C110 | JI et al., Regulated antisense RNA eliminates alpha-toxin virulence in Staphylococcus aureus infection. J Bacteriol. 1999 Nov;181(21):6585-90. | |
| | C111 | JI et al., Identification of critical staphylococcal genes using conditional phenotypes generated by antisense RNA. Science. 2001 Sep 21;293(5538):2266-9. | |
| | C112 | KOLBERG et al., Monoclonal antibodies with specificities for Streptococcus pneumoniae group 9 capsular polysaccharides. FEMS Immunol Med Microbiol. 1998 Apr;20(4):249-55. Abstract Only. | |
| | C113 | LONGWORTH et al., O-Acetylation status of the capsular polysaccharides of serogroup Y and W135 meningococci isolated in the UK. FEMS Immunol Med Microbiol. 2002 Jan 14;32(2):119-23. Abstract Only. | |
| | C114 | MACK et al., Molecular mechanisms of Staphylococcus epidermidis biofilm formation. J Hosp Infect. 1999 Dec;43 Suppl:S113-25. Abstract Only. | |
| | C115 | MACK et al., Genetic and biochemical analysis of Staphylococcus epidermidis biofilm accumulation. Methods Enzymol. 2001;336:215-39. | |
| | C116 | McNEELY et al., Antibody responses to capsular polysaccharide backbone and O-acetate side groups of Streptococcus pneumoniae type 9V in humans and rhesus macaques. Infect Immun. 1998 Aug;66(8):3705-10. | |
| | C117 | MICHON et al., Structure activity studies on group C meningococcal polysaccharide-protein conjugate vaccines: effect of O-acetylation on the nature of the protective epitope. Dev Biol (Basel). 2000;103:151-60. Abstract Only. | |
| | C118 | MULLER et al., Capsular polysaccharide/adhesin (PS/A) production by coagulase-negative staphylococci (CNS) is associated with adherence to silastic tubing. 1989. Page 49. Abstract B-111. | |

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __, filed __, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

| | |
|-----------|------------------|
| EXAMINER: | DATE CONSIDERED: |
|-----------|------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.